Michael F. Press, MD, PhD
Los Angeles, California
Professor of Pathology
Harold E. Lee Chair in Cancer Research
Director of Breast Cancer Analysis Lab
Keck School of Medicine
Refining breast cancer biomarkers for predicting response to targeted therapies in order to improve personalized medicine.
Breast cancer molecular markers, such as HER2, estrogen receptor, and progesterone receptor, are used in a clinical setting to select treatments for patients. Because they act as major drivers of breast cancer, they have been successful therapeutic targets. Dr. Press and his team are working to improve treatment response using known biomarkers and to identify new breast cancer biomarkers to help guide treatment decisions and reduce drug resistance. This work may improve patient selection for existing therapies and identify new targets for therapy.
The team is involved in several research projects that could impact personalized medicine for breast cancer patients. During the last year, the team completed a series of collaborative studies to characterize the association of molecular alterations—particularly HER2 gene amplification, steroid hormone receptor status, and the presence of a marker known as Ki67—with responsiveness to various treatments. They also continued long-standing collaborative studies to identify breast cancer risk elements in the genome, especially in women of African ancestry. In another study, they identified increased breast cancer risk, particularly for HER2-positive breast cancers among African American women who smoke cigarettes.
In the coming year, the team will continue their work refining current biomarkers used to define HER2-positive breast cancer to better understand how this molecular driver might vary between patients. Specifically, the team will compare response to treatments based on different biomarkers used to define HER2 levels in patient samples. Dr. Press and his team will also track changes in HER2 in the tumor cells during tumor progression and metastasis to see if there is any variability in the proportion of tumor cells with HER2 gene amplification within a single tumor.
Dr. Press is a Professor in the Department of Pathology and holds the Harold E. Lee Chair in Cancer Research at the University of Southern California’s Norris Comprehensive Cancer Center. Dr. Press is a board certified pathologist, directs the USC Breast Cancer Analysis Laboratory as well as the Central Laboratory for the Translational Research In Oncology (TRIO)/Cancer International Research Group (CIRG), and is Leader of the USC Clinical Laboratories.
His laboratory evaluates prognostic and predictive markers used in making treatment decisions for women with breast cancer. It has served as the Central Laboratory for either retrospective or prospective analyses of tissue specimens for 18 clinical trials that collectively accrued more than 13,000 patients. Dr. Press’s area of research interest is in molecular alterations of breast and gynecologic cancers, especially those that have the potential to be important in either diagnostic or therapeutic decision-making for patient management. His research has been continuously funded by research grants for more than 25 years. He is the author or co-author of more than 200 peer-reviewed publications. The most prominent area of activity for his laboratory has been in the study of the human epidermal growth factor receptor type 2 (HER2) in breast and other cancers. He published his first paper in this area in 1989 (Science 244: 707-712) and his laboratory is still actively contributing to this area as well as to the conduct of clinical trials evaluating HER2 as a target for therapy.
When you give to BCRF, you're funding critical hours in the lab. More time for research means longer, healthier lives for the ones we love.